| Literature DB >> 33836719 |
Ikechukwu A Orji1, Abigail S Baldridge2, Kasarachi Omitiran3, Mainzhao Guo2, Whenayon Simeon Ajisegiri4, Tunde M Ojo3, Gabriel Shedul3, Namratha R Kandula2, Lisa R Hirschhorn2, Mark D Huffman2,4, Dike B Ojji3,5.
Abstract
BACKGROUND: Nigeria faces an increase in the burden of non-communicable diseases (NCDs), including cardiovascular diseases (CVDs), leading to an estimated 29% of all deaths in the country. Nigeria has an estimated hypertension prevalence ranging from 25 to 40% of her adult population. Despite this high burden, awareness (14-30%), treatment (< 20%), and control (9%) rates of hypertension are low in Nigeria. Against this backdrop, we sought to perform capacity and readiness assessments of public Primary Healthcare Centers (PHCs) to inform Nigeria's system-level hypertension control program's implementation and adaptation strategies.Entities:
Keywords: Capacity; Hypertension; Nigeria; Primary health care; Readiness
Mesh:
Year: 2021 PMID: 33836719 PMCID: PMC8034094 DOI: 10.1186/s12913-021-06320-8
Source DB: PubMed Journal: BMC Health Serv Res ISSN: 1472-6963 Impact factor: 2.655
Fig. 1STROBE Site Flow Chart. Of 243 Primary Healthcare Centers within the Federal Capital Territory, Abuja, Nigeria, 90 were excluded based on having fewer than two full-time staff, security concerns, no or poor road access or lack of functionality by providing patient services at the time of the assessment. Of the remaining 153 Primary Healthcare Centers, multistage random selection was applied to select 60 for inclusion in the study
Fig. 2Selected Primary Healthcare Centers within the Federal Capital Territory. The 60 Primary Healthcare Centers selected for the study represent broad geographic diversity within the Federal Capital Territory, depicted here with wards represented in black lines. Some of the selected sites (black) have a ward-level focal person based within the site, and some (blue) are sites of interest for the FCT Primary Health Care Board for Basic Health Care Provision Fund (BHCPF) project. Many sites (yellow) are both
Capacity and Readiness in Federal Capital Territory, Nigeria, for Implementing System-Level Hypertension Control Program within 60 Primary Healthcare Centers
| Site Characteristics | No. Sites Responded | Result |
|---|---|---|
| Personnel and Training | ||
| Sites with two or more full-time staff, a n (%) | 54 | 54 (90) |
| Number of full-time healthcare professionals, median (IQR) | 60 | 5 (3–8) |
| Full-time community health extension workers, median (IQR) | 60 | 3 (2–5) |
| Full-time nurses, median (IQR) | 60 | 1 (0–2) |
| Full-time doctors (generalists and specialists), median (IQR) | 60 | 0 (0–0) |
| Received CVD training within the past 2 years, n (%) | 55 | 8 (15) |
| Hypertension Service Delivery | ||
| Screen for hypertension status, n (%) | 60 | 58 (97) |
| Diagnose hypertension, n (%) | 60 | 56 (93) |
| Confirm hypertension diagnosis, n (%) | 60 | 50 (83) |
| Dispense initial treatment for hypertension, n (%) | 60 | 34 (57) |
| Dispense follow-up treatment for hypertension, n (%) | 60 | 34 (57) |
| Monitor patients with hypertension, n (%) | 60 | 48 (80) |
| Provide long term care for patients with hypertension, n (%) | 60 | 36 (60) |
| Equipment and Supplies for Hypertension | ||
| Guidelines, n (%) | 55 | 7 (13) |
| Treatment algorithms, n (%) | 55 | 3 (5) |
| Information, education, and communication, n (%) | 55 | 1 (2) |
| Functional blood pressure apparatus, n (%) | 60 | 55 (92) |
| Information Systems | ||
| Use of electronic patient records, n (%) | 60 | 0 (0) |
| Functional landline phone, n (%) | 60 | 13 (22) |
| Functional cellular phone, n (%) | 60 | 29 (48) |
| Functional computer, n (%) | 60 | 10 (17) |
| Access to email or internet, n (%) | 60 | 5 (8) |
| Availability of Blood Pressure Lowering Medications | ||
| Angiotensin Converting Enzyme Inhibitor, n (%) | 59 | 10 (17) |
| Angiotensin Receptor Blocker, n (%) | 59 | 3 (5) |
| Beta Blocker, n (%) | 59 | 5 (8) |
| Calcium Channel Blocker, n (%) | 59 | 19 (32) |
| Central acting agent, n (%) | 59 | 11 (19) |
| Fixed Dose Combinations, n (%) | 59 | 4 (7) |
| Diuretic,b n (%) | 59 | 15 (25) |
| Vasodilator, n (%) | 59 | 4 (7) |
| Number of 30-day treatment regimens in stock, median (IQR) | 59 | 0 (0–20) |
| No 30-day treatment regimens in stock, n (%) | 59 | 35 (59) |
CVD Cardiovascular Disease, IQR Inter-Quartile Range
aIncluding all reported full-time clinicians or paramedics, nursing professionals, pharmacists, laboratory technicians, community health extension workers, and community health officers
bIncluding furosemide, spironolactone, thiazide or other diuretic
Fig. 3Hypertension Treatment Cascade by Council Area. Steps within the hypertension treatment cascade are shown along the x-axis, including screening, diagnosis, confirmation, treatment at initial diagnosis and at follow-up, monitoring and long-term continued care services. The proportion of primary healthcare centers within each area council who self-reported providing these services are shown by bars. Diagnosis: high blood pressure (> 140/90 mmHg) after measuring two or three times at 1–2 min intervals preceded by 3–5 min rest. Confirmation: defined as persistent high blood pressures (> 140/90 mmHg) after two or three clinic visits at 1–4 weeks intervals. Dispense initial treatment: occurs at the first visit, when a patient who has been confirmed as hypertensive is given the first 1-month course of treatment. Dispense follow-up treatment: occurs during routine monthly follow-up visit. Long term care: follow-up of patient’s treatment over several months to years
General and Cardiovascular Disease Service Availability and Readiness Indicators for 60 Primary Healthcare Center in the Federal Capital Territory, Nigeria
| Service Availability and Readiness Indicator | Local Government Area Council | |||||
|---|---|---|---|---|---|---|
| Abaji ( | AMAC ( | Bwari ( | Gwagwalada ( | Kuje ( | Kwali ( | |
| General Service Readiness | ||||||
| Basic Amenitiesb | 52.1 | 48.9 | 56.3 | 43.9 | 41.7 | 28.3 |
| Basic Equipmentc | 67.5 | 80.0 | 100.0 | 70.9 | 57.5 | 74.0 |
| Infection Preventiond | 93.8 | 56.7 | 81.3 | 68.2 | 75.0 | 90.0 |
| Diagnostic Capacitye | 59.4 | 83.3 | 90.6 | 61.4 | 62.5 | 62.5 |
| Essential Medicinesf | 6.3 | 24.4 | 29.2 | 13.6 | 6.3 | 5.0 |
| Cardiovascular Disease Service Availability | ||||||
| Availabilityg | 100.0 | 100.0 | 100.0 | 100.0 | 87.5 | 90.0 |
| Cardiovascular Disease Readiness Indicators | ||||||
| Guidelinesh | 12.5 | 6.7 | 0.0 | 0.0 | 0.0 | 20.0 |
| Equipmenti | 70.9 | 84.4 | 100 | 69.7 | 66.7 | 73.4 |
| Medicinesj | 7.5 | 28.0 | 30.0 | 16.4 | 7.5 | 6.0 |
aEach indicator is calculated as the proportion of amenities, equipment, diagnostic tests, or medicines within a defined SARA domain
bThe item “Room with auditory and visual privacy for patient consultations” was not included
cThe item “Child scale” was not included
dThe items “Safe final disposal of infectious wastes”, “Appropriate storage of sharps waste”, “Appropriate storage of infectious waste”, “Disinfectant”, “Single use —standard disposable or auto-disable syringes”, “Soap and running water or alcohol-based hand rub” and “Latex gloves” were not included
eThe items “Malaria diagnostic capacity”, “HIV diagnostic capacity”, “Syphilis rapid test” and “Urine test for pregnancy” were not included
fItems “CCB”, “Aspirin”, “Beta Blockers”, “ACE”, “Statin” and “Thiazide” were included
gCalculated as the proportion of facilities offering cardiovascular disease diagnosis and/or management
hThe item “guidelines for diagnosis and treatment of chronic cardiovascular conditions” was included
iThe items “Stethoscope”, “Blood pressure apparatus” and “Adult scale” were included
jThe items “CCB”, “Aspirin”, “Beta Blockers”, “ACE” and “Thiazide” were included
Fig. 4Drugs Available for 30-Day Regimens by Drug Class among Selected PHCs (n = 59). The number of 30-day treatment regimens in stock of the day of assessment were tabulated by drug class. Most sites had no 30-day treatment regimens in stock. Of the drugs that were stocked, calcium channel blockers, central acting agents, diuretics and angiotensin converting enzymes inhibitors (ACE-I) were most common